NASMAC is a joint venture pharmaceutical company founded in Saudi Arabia by two giant ventures: Macleods Pharma Laboratories (a top Indian pharmaceutical company with 45 years of experience) and Zahran Holding Company (one of the top 100 Saudi companies). We focus on developing innovative, accessible, and locally manufactured solutions for non-communicable diseases.
NASMAC focuses on medications for non-communicable diseases with high prevalence in Saudi Arabia, including treatments for neuropsychiatry disorders, diabetes, cardiovascular disease, cancer, obesity, and respiratory conditions like Asthma/COPD. We are establishing the first production facilities in Saudi Arabia for oral cytotoxic drugs and respiratory inhalers.
NASMAC directly supports Vision 2030 through: Localizing pharmaceutical manufacturing to achieve 40-50% localization within 10 years, Creating high-value jobs in life sciences, Reducing dependency on pharmaceutical imports, Transferring technology and knowledge to build local expertise, and Improving healthcare outcomes for Saudi citizens.
NASMAC combines international pharmaceutical excellence from Macleods (with 6 US FDA-approved facilities) with deep local market knowledge from Zahran Holding. We are establishing GMP-certified production facilities specifically for unmet needs in Saudi Arabia, including first-in-Kingdom manufacturing of oral cytotoxic drugs and respiratory inhalers.
Quality is paramount at NASMAC. We leverage Macleods' 45 years of experience and US FDA-approved facilities, implement GMP-certified production standards, and utilize technology transfer agreements with international pharmaceutical partners to ensure the highest quality and safety standards.
Macleods Pharma Laboratories is one of our founding partners, bringing 45 years of pharmaceutical expertise, 13 manufacturing facilities (6 US FDA approved), and a rich product portfolio. This partnership provides NASMAC with proven manufacturing capabilities, international quality standards, and access to advanced pharmaceutical technologies.
Yes, NASMAC invests in research and development focusing on unmet needs in non-communicable diseases prevalent in Saudi Arabia. We develop biopharmaceuticals and advanced generics, and form strategic partnerships with leading international biotech and pharmaceutical companies to bring innovative solutions to the Kingdom.
NASMAC is committed to talent development and knowledge transfer, supporting Vision 2030's goals of creating high-value jobs in life sciences. We offer opportunities in pharmaceutical manufacturing, research and development, quality assurance, regulatory affairs, and more. We provide technology transfer and training to build local expertise.
For partnership opportunities, business development, or investment inquiries, please visit our Contact page or reach out to our dedicated team at info@nasmac.com.sa
We welcome collaborations with international pharmaceutical companies, healthcare institutions, and government entities.
